<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523599</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-014</org_study_id>
    <nct_id>NCT02523599</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty</brief_title>
  <acronym>MATRIX-1</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled&#xD;
      efficacy and safety study of postoperative pain in adults who are scheduled for unilateral&#xD;
      inguinal hernioplasty via open laparotomy (tension-free technique).&#xD;
&#xD;
      Patients will assess their postoperative pain intensity (PI) using an 11-point numerical&#xD;
      rating scale (NRS) from 0 hour through 72 hours postoperatively.&#xD;
&#xD;
      The expected maximum study duration for each patient will be up to 60 days, including a&#xD;
      maximum 30-day screening period, the day of surgery and implantation, and a 30-day post&#xD;
      implantation period including treatment and follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled&#xD;
      study in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy&#xD;
      (tension-free technique). Patients will receive either 3 XaraColl Bupivacaine Implants each&#xD;
      containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3&#xD;
      placebo-sponges.&#xD;
&#xD;
      Three test article sponges will be implanted according to the patient's blinded treatment&#xD;
      assignment. Following surgery, patients will be transferred to a postanesthesia care unit&#xD;
      (PACU) and/or other postoperative recovery area for observation where they may receive&#xD;
      parenteral morphine as needed (rescue medication for breakthrough pain) and on request for&#xD;
      pain control. Once patients can tolerate oral medication, they will commence a standardized&#xD;
      oral analgesic regimen with additional PRN medication to manage breakthrough pain only when&#xD;
      it occurs.&#xD;
&#xD;
      Patients will assess their postoperative pain intensity (PI) using an 11-point numerical&#xD;
      rating scale (NRS) from 0 hour through 72 hours postoperatively.&#xD;
&#xD;
      Patients will be observed postoperatively for a minimum of 3 hours and may be discharged at&#xD;
      any time following completion of their 3-hour vital sign and PI assessments. Patients will be&#xD;
      contacted at approximately 6, 24 and 48 hours after implantation to ensure protocol&#xD;
      compliance and to perform safety assessments (including AEs and concomitant medications). At&#xD;
      72 hours, patients will return to the clinic to perform their final PI assessment, complete a&#xD;
      categorical assessment of their overall pain control, and for follow-up safety assessments.&#xD;
      They will also be asked to record the incidence of any ongoing or subsequent AEs (and any&#xD;
      associated treatment) through Day 7. Additional follow-up assessments for safety will be&#xD;
      performed at postoperative Day 7 (telephone call) and Days 15 and 30 (clinic visits).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPI24</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Sum of Pain Intensity (SPI24). The time weighted sum of pain intensity from 0 to 24 hours (ie, the area under the NRS PI curve from 0 to 24 hours). Where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. This type of measurement scale is called &quot;NRS&quot; or Numerical Rating Scale For the purpose of (SPI) computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. SPI will not be calculated for randomized but not treated patients. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TOpA24</measure>
    <time_frame>Time 0 through 24 hours</time_frame>
    <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24). This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 24 hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOpA48</measure>
    <time_frame>Time 0 through 48 hours</time_frame>
    <description>Total use of Opioid Analgesia from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOpA72</measure>
    <time_frame>Time 0 through 72 hours</time_frame>
    <description>Total use of Opioid Analgesia (TOpA) from Time 0 through 72 hours. This is a basic measurement of counting in total the number of morphine tablets patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPI48</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Sum of pain intensity (SPI).The time weighted sum of pain intensity from 0 to 48 hours (ie, the area under the NRS PI curve from 0 to 48 hours). For the purpose of SPI computation, Pain Intensity at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPI72</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Sum of pain intensity (SPI). The time weighted sum of pain intensity from 0 to 72 hours (ie, the area under the NRS PI curve from 0 to 72 hours). For the purpose of SPI computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Where 0 indicates &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>XaraColl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 placebo implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XaraColl</intervention_name>
    <description>Surgical implantation of 3 bupivacaine collagen implants</description>
    <arm_group_label>XaraColl</arm_group_label>
    <other_name>Bupivacaine collagen implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Plain collagen implant (vehicle)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a planned (non-emergent) unilateral inguinal hernioplasty (open laparotomy,&#xD;
             tension-free technique) to be performed according to standard surgical technique under&#xD;
             general anesthesia. Repair of multiple hernias through a single incision is permitted&#xD;
             provided only a single mesh will be used.&#xD;
&#xD;
          -  If female, is nonpregnant and nonlactating.&#xD;
&#xD;
          -  If female, is either not of childbearing potential (defined as postmenopausal for ≥ 1&#xD;
             year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or&#xD;
             hysterectomy]) or practicing 1 of the protocol specified medically-acceptable methods&#xD;
             of birth control and agrees to continue with the regimen throughout the duration of&#xD;
             the study:&#xD;
&#xD;
          -  Has the ability and willingness to comply with the study procedures and use of the&#xD;
             eDiary.&#xD;
&#xD;
          -  Is willing to use only permitted medications throughout the study.&#xD;
&#xD;
          -  Is willing to use opioid analgesia.&#xD;
&#xD;
          -  Must be able to fluently speak and understand either English or Spanish and be able to&#xD;
             provide meaningful written informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known hypersensitivity to amide local anesthetics, morphine, acetaminophen or&#xD;
             bovine products.&#xD;
&#xD;
          -  Is scheduled for bilateral inguinal hernioplasty or other significant concurrent&#xD;
             surgical procedures per investigator discretion.&#xD;
&#xD;
          -  Has undergone major surgery within 3 months of the scheduled hernioplasty or plans to&#xD;
             undergo another laparotomy procedure within 30 days postoperatively.&#xD;
&#xD;
          -  Has used any analgesic other than acetaminophen within 24 hours of surgery.&#xD;
             Acetaminophen may be used on the day of surgery but is subject to preoperative&#xD;
             restrictions for oral intake.&#xD;
&#xD;
          -  Has used aspirin or aspirin-containing products within 7 days of surgery. Aspirin at a&#xD;
             dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on&#xD;
             a stable dose regimen for ≥ 30 days before Screening.&#xD;
&#xD;
          -  Has used systemic steroids, anticonvulsants, antiepileptics, antidepressants for the&#xD;
             management of chronic pain, or monoamine oxidase inhibitors on a regular basis within&#xD;
             10 days of surgery.&#xD;
&#xD;
          -  Has used any opioid analgesic for an extended daily basis (30 - 60 mg oral morphine&#xD;
             equivalent per day for 3 or more days a week) within 4 weeks before surgery. Patients&#xD;
             who, in the investigator's opinion, may be developing opioid tolerance are also&#xD;
             excluded.&#xD;
&#xD;
          -  Has any chronic painful condition (eg, fibromyalgia) or routinely uses pain medication&#xD;
             other than acetaminophen (including nonsteroidal anti-inflammatory drugs [NSAIDs])&#xD;
             that, in the opinion of the investigator, may confound the assessment of pain&#xD;
             associated with the hernioplasty.&#xD;
&#xD;
          -  Has a physical or mental condition that, in the opinion of the investigator, may&#xD;
             confound the assessment of postoperative pain after hernioplasty.&#xD;
&#xD;
          -  Shows evidence of tolerance or physical dependency on opioid analgesics or&#xD;
             sedative-hypnotic medications.&#xD;
&#xD;
          -  Has a urine drug screen that tests positive for drugs of abuse or misuse, including&#xD;
             cannabinoids.&#xD;
&#xD;
          -  Has liver function test results greater than 3x the upper limit of normal or a history&#xD;
             of cirrhosis.&#xD;
&#xD;
          -  Has any clinically significant unstable cardiac disease (eg, uncontrolled&#xD;
             hypertension, clinically significant arrhythmia at baseline, or an implantable&#xD;
             cardioverter-defibrillator [ICD])&#xD;
&#xD;
          -  Has any clinically significant unstable neurological, immunological, renal, or&#xD;
             hematological disease (eg, uncontrolled diabetes or significantly abnormal laboratory&#xD;
             findings), or any other condition that, in the opinion of the investigator, could&#xD;
             compromise the patient's welfare, ability to communicate with the study staff or&#xD;
             otherwise contraindicate study participation.&#xD;
&#xD;
          -  Has an open workman's compensation claim.&#xD;
&#xD;
          -  Has participated in a clinical trial (investigational or marketed product) within 30&#xD;
             days of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwendolyn Niebler, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont</city>
        <state>Florida</state>
        <zip>34711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post operative pain</keyword>
  <keyword>hernioplasty</keyword>
  <keyword>bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not return for Day 30 visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="12.82"/>
                    <measurement group_id="B2" value="53.3" spread="14.01"/>
                    <measurement group_id="B3" value="53.1" spread="13.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SPI24</title>
        <description>Sum of Pain Intensity (SPI24). The time weighted sum of pain intensity from 0 to 24 hours (ie, the area under the NRS PI curve from 0 to 24 hours). Where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. This type of measurement scale is called &quot;NRS&quot; or Numerical Rating Scale For the purpose of (SPI) computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. SPI will not be calculated for randomized but not treated patients. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI24</title>
          <description>Sum of Pain Intensity (SPI24). The time weighted sum of pain intensity from 0 to 24 hours (ie, the area under the NRS PI curve from 0 to 24 hours). Where 0 indicated &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. This type of measurement scale is called &quot;NRS&quot; or Numerical Rating Scale For the purpose of (SPI) computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. SPI will not be calculated for randomized but not treated patients. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>mITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="47.18"/>
                    <measurement group_id="O2" value="106.8" spread="48.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA24</title>
        <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24). This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 24 hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 24 hours</time_frame>
        <population>(mITT Population)</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA24</title>
          <description>Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24). This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 24 hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <population>(mITT Population)</population>
          <units>morphine mg equivalent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="47"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA48</title>
        <description>Total use of Opioid Analgesia from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 48 hours</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA48</title>
          <description>Total use of Opioid Analgesia from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <population>mITT Population</population>
          <units>morphine mg equivalent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="82.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="0.0" upper_limit="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TOpA72</title>
        <description>Total use of Opioid Analgesia (TOpA) from Time 0 through 72 hours. This is a basic measurement of counting in total the number of morphine tablets patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
        <time_frame>Time 0 through 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>TOpA72</title>
          <description>Total use of Opioid Analgesia (TOpA) from Time 0 through 72 hours. This is a basic measurement of counting in total the number of morphine tablets patients had use within a 72-hour period (typically called &quot;rescue&quot; to help manage pain. Zero (0) is the &quot;lowest&quot; score. The lower the number of tablets the better outcome.</description>
          <units>morphine mg equivalent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="102.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPI48</title>
        <description>Sum of pain intensity (SPI).The time weighted sum of pain intensity from 0 to 48 hours (ie, the area under the NRS PI curve from 0 to 48 hours). For the purpose of SPI computation, Pain Intensity at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 48 hours</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI48</title>
          <description>Sum of pain intensity (SPI).The time weighted sum of pain intensity from 0 to 48 hours (ie, the area under the NRS PI curve from 0 to 48 hours). For the purpose of SPI computation, Pain Intensity at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Minimum value would be &quot;0&quot; and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>mITT Population</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.7" lower_limit="0.0" upper_limit="408.9"/>
                    <measurement group_id="O2" value="190.1" lower_limit="6.6" upper_limit="470.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SPI72</title>
        <description>Sum of pain intensity (SPI). The time weighted sum of pain intensity from 0 to 72 hours (ie, the area under the NRS PI curve from 0 to 72 hours). For the purpose of SPI computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Where 0 indicates &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
        <time_frame>0 to 72 hours</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>XaraColl</title>
            <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
          </group>
        </group_list>
        <measure>
          <title>SPI72</title>
          <description>Sum of pain intensity (SPI). The time weighted sum of pain intensity from 0 to 72 hours (ie, the area under the NRS PI curve from 0 to 72 hours). For the purpose of SPI computation, PI at Time 0 (Baseline PI) is set to zero for all patients who have test article implantation. Where 0 indicates &quot;no pain&quot; and 10 indicated &quot;worst pain possible&quot;. A lower score is a better outcome. Minimum value would be &quot;0&quot; and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑[PI x (time t - time t-1)], where &quot;t&quot; represents a given time point,&quot;t-1&quot; represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.</description>
          <population>mITT Population</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.2" lower_limit="0.0" upper_limit="594.1"/>
                    <measurement group_id="O2" value="263.3" lower_limit="6.6" upper_limit="710.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>A total of 204 patients have been randomized to INL-001 active drug arm. However 1 patient was randomized and not treated. This means only 203 patients received the active compound. In the Placebo arm all patient randomized were treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>XaraColl</title>
          <description>3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose&#xD;
XaraColl: Surgical implantation of 3 bupivacaine collagen implants</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>3 placebo implants&#xD;
Placebo: Plain collagen implant (vehicle)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>intestinal ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>peritonitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="203"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>incision site pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="203"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>incision site swelling</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="203"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>post procedural discharge</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="203"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="203"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="203"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

